Oncopeptides

Oncopeptides EBIT

The EBIT of Oncopeptides (ONCO.ST) as of Nov 10, 2026 is -228.93 M SEK. In the previous year, EBIT was -283.50 M SEK — a change of -19.25% (higher).

EBIT

-228.93 MSEK

YoY

-19.25%

Last updated:

In 2025, Oncopeptides's EBIT was -228.93 M SEK, a -19.25% increase from the -283.50 M SEK EBIT recorded in the previous year.

The Oncopeptides EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2022
-349.35 M SEK
Jan 1, 2023
-253.45 M SEK
Jan 1, 2024
-283.50 M SEK
Jan 1, 2025
-228.93 M SEK
Jan 1, 2026 (e)
-96.81 M SEK
Jan 1, 2027 (e)
-40.09 M SEK
Jan 1, 2028 (e)
4.18 M SEK
Jan 1, 2029 (e)
-688.83 M SEK
The Oncopeptides EBIT history
YEAREBITYoY
est-688.83 MSEK-16,581.83%
est4.18 MSEK-110.43%
est-40.09 MSEK-58.59%
est-96.81 MSEK-57.71%
-228.93 MSEK-19.25%
-283.50 MSEK+11.86%
-253.45 MSEK-27.45%
-349.35 MSEK-75.41%
-1.42 BSEK-10.69%
-1.59 BSEK+115.17%
-739.39 MSEK+75.99%
-420.14 MSEK+69.67%
-247.62 MSEK+116.30%
-114.48 MSEK+114.59%
-53.35 MSEK+61.13%
-33.11 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncopeptides Revenue

Oncopeptides Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
8.36 M SEK
-349.35 M SEK
-337.95 M SEK
Jan 1, 2023
35.22 M SEK
-253.45 M SEK
-249.11 M SEK
Jan 1, 2024
31.65 M SEK
-283.50 M SEK
-284.61 M SEK
Jan 1, 2025
71.12 M SEK
-228.93 M SEK
-249.59 M SEK
Jan 1, 2026 (e)
129.00 M SEK
-96.81 M SEK
-122.82 M SEK
Jan 1, 2027 (e)
251.67 M SEK
-40.09 M SEK
-58.18 M SEK
Jan 1, 2028 (e)
333.33 M SEK
4.18 M SEK
-7.76 M SEK
Jan 1, 2029 (e)
688.83 M SEK
-688.83 M SEK
0.00 SEK

Oncopeptides Margins

Oncopeptides stock margins

The Oncopeptides margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oncopeptides. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oncopeptides.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
99.93 %
-4,181.33 %
-4,044.90 %
Jan 1, 2023
103.06 %
-719.61 %
-707.30 %
Jan 1, 2024
91.59 %
-895.78 %
-899.29 %
Jan 1, 2025
82.96 %
-321.89 %
-350.94 %
Jan 1, 2026 (e)
82.96 %
-75.05 %
-95.21 %
Jan 1, 2027 (e)
82.96 %
-15.93 %
-23.12 %
Jan 1, 2028 (e)
82.96 %
1.25 %
-2.33 %
Jan 1, 2029 (e)
82.96 %
-100.00 %
0.00 %

Oncopeptides Stock analysis

What does Oncopeptides do? Oncopeptides AB is a biopharmaceutical company specializing in the research and development of novel therapeutics for the treatment of cancer. The company was founded in 2000 in Uppsala, Sweden. Oncopeptides' research focuses on the discovery of substances that can affect specific cellular processes, inhibiting or even killing the growth of cancer cells. The company places particular emphasis on the development of drugs that can be targeted against specific types of cancer and have minimal side effects. The business model of Oncopeptides is based on licensing developed drugs to other companies or marketing their own products. This allows for faster progress in development and minimizes entrepreneurial risk. The company is divided into three different divisions, focusing on different types of cancer. The first division specializes in the treatment of multiple myeloma, the second in the treatment of solid tumors, and the third in the development of diagnostic tests for early cancer detection. The first product that Oncopeptides has brought to market is the drug Ygalo. It is used to treat patients with advanced multiple myeloma who do not respond to other therapies. Ygalo is a peptide mimetic specifically designed to inhibit the protein MCL-1, which plays a key role in cell proliferation in many types of cancer. In the second division of Oncopeptides, the company focuses on the development of drugs that can be specifically targeted against solid tumors such as lung, breast, or colorectal cancer. The protein BET inhibitor is targeted, which plays an important role in the regulation of gene expression in many types of cancer. The third division of Oncopeptides is engaged in the development of diagnostic tests that enable early detection of cancer. Both blood tests and imaging techniques are used to detect changes in the body that could indicate cancer. The focus is on the development of tests that can detect early signs of cancer, enabling timely diagnosis and treatment. Overall, Oncopeptides is a promising company specializing in the development of innovative therapeutics in cancer treatment. With its focus on specific cellular processes and targeted approaches to fighting different types of cancer, the company is on a promising path to bring more products to market that can improve the lives of many cancer patients. Oncopeptides is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Oncopeptides's EBIT

Oncopeptides's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Oncopeptides's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Oncopeptides's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Oncopeptides’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Oncopeptides stock

EBIT of Oncopeptides is -228.93 M SEK in 2025.

EBIT of Oncopeptides changed from -283.50 M SEK to -228.93 M SEK, representing a -19.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Oncopeptides since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Oncopeptides historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Oncopeptides

All Key Metrics — Oncopeptides